NVDA−4.40%AAPL+1.23%GOOGL−3.15%MSFT−2.23%AMZN−4.57%TSM−4.52%SPCX−9.14%META−6.98%
StockVS

NASDAQ · Biotechnology · USD

Kardigan, Inc. (KARD) Stock Analysis

Kardigan, Inc. (KARD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 22, 2026

KARD

$12.74

−$0.11 (−0.86%)

Oct 22, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KARD with… →

KARD Key Statistics

As of Oct 22, 2026
Trading
Open
$12.86
Previous Close
$12.85
Day's Range
12.40–13.05
52-Week Range
12.23–27.00
Volume
380.80K
Valuation
Market Cap
$1.19B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−10.65
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$191.94M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
93.50M
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
525.44K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Kardigan, Inc. (KARD) has a market capitalization of $1.19B.

In fiscal 2025, KARD reported revenue of $0.00.

KARD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$191.94M—
2024$0.00−$88.66M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$201.84M−$191.94M—
2024$0.00—−$96.66M−$88.66M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Kardigan, Inc. (KARD) is capitalised at $1.19B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 241.

KARD last closed at $12.74 on October 22, 2026. That is −$0.11 (−0.86%) against the previous close. The 52-week range on file runs from $12.23 to $27.00. The latest close sits 4.17% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $191.94M. Trailing earnings per share are −10.65.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Growth & Income

No dividend is on file for KARD.

2026 is still running; the total return is −42.09% year to date.

Peer Comparison

Kardigan, Inc. (KARD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Kardigan, Inc. KARD $1.19B —
Vertex Pharmaceuticals Incorporated VRTX $135.64B 31.0
Regeneron Pharmaceuticals, Inc. REGN $84.33B 20.3
Moderna, Inc. MRNA $80.90B —

The Biotechnology industry average P/E ratio is 16.6x. Kardigan, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 22, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$135.64B

 REGN

Regeneron Pharmaceuticals, Inc.

$84.33B

 MRNA

Moderna, Inc.

$80.90B

 ARGX

argenx SE

$55.07B

 ONC

BeOne Medicines AG

$43.49B

 RVMD

Revolution Medicines, Inc.

$40.23B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.17T

 JNJ

Johnson & Johnson

$644.91B

 ABBV

AbbVie Inc.

$503.96B

 UNH

UnitedHealth Group Incorporated

$381.46B

 MRK

Merck & Co., Inc.

$363.27B
View all Healthcare stocks →

About Kardigan, Inc.

Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The company incorporates Prolaio's cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence. The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments. Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector. The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024. The company was founded in 2023 and is based in Princeton, New Jersey.

Visit website →